Brand/Generic Settlement Bill Advances; Will Debate Come Down To FTC v. CBO?
Executive Summary
After clearing the Senate Judiciary Committee on Oct. 15, the next hurdle for legislation that would curtail settlement deals between brand firms and generic challengers may be obtaining a favorable score from the Congressional Budget Office
You may also be interested in...
FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"
Potential Federal Trade Commission rule-making looms over the contentious issue of "pay -for-delay" in brand/generic settlements, particularly as the judicial and legislative environments remain uncertain.
FTC Rulemaking Could Be Next (And Last?) Attempt To Curb "Pay-For-Delay"
Potential Federal Trade Commission rule-making looms over the contentious issue of "pay -for-delay" in brand/generic settlements, particularly as the judicial and legislative environments remain uncertain.
Reverse Settlements: FTC Commissioner, Circuit Judge, Former Solicitor General Debate When A Deal Is Acceptable
Key players in the battle over reverse settlements between brand name and generic drug manufacturers offered ways to resolve the issue at a recent in-house counsel forum on pharmaceutical antitrust